acute pancreatitis
Conditions
Interventions
experimental group:treat with low molecular weight heparin
control group:conventional therapy
Sponsors
Department of Gastroenterology, Institute of Surgery Research, Daping Hospital, Third Military Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Conform to the diagnostic criteria of acute pancreatitis; 2. Aged 18-75 years old, male and female are not restricted; 3. Be able to understand the procedures and methods of this clinical research, participate in voluntarily and sign informed consent.;Inclusion criteria: 1. Conform to the diagnostic criteria of acute pancreatitis; 2. Aged 18-75 years old, male and female are not restricted; 3. Be able to understand the procedures and methods of this clinical research, participate in voluntarily and sign informed consent.;Inclusion criteria: 1. Conform to the diagnostic criteria of acute pancreatitis; 2. Aged 18-75 years old, male and female are not restricted; 3. Be able to understand the procedures and methods of this clinical research, participate in voluntarily and sign informed consent.;Inclusion criteria: 1. Conform to the diagnostic criteria of acute pancreatitis; 2. Aged 18-75 years old, male and female are not restricted; 3. Be able to understand the procedures and methods of this clinical research, participate in voluntarily and sign informed consent.;Inclusion criteria: 1. Conform to the diagnostic criteria of acute pancreatitis; 2. Aged 18-75 years old, male and female are not restricted; 3. Be able to understand the procedures and methods of this clinical research, participate in voluntarily and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who have accepted drug treatment outside of hospital; 2. patients who have long-term used antiplatelet or anticoagulant drugs; 3. patients with hematological diseases; 4. patients with trauma, fracture, stroke, paralysis, long-term bedridden, central venous catheter, Crohn's disease, nephrotic syndrome, long-term use of estrogen, malignant tumor, heart and lung failure, oral contraceptives, venous thromboembolism disease; 5. patients who are allergic to any excipient of low molecular heparin or low molecular weight heparin injection; 6. patients who have thrombocytopenia history while using low molecular weight heparin; 7. patients with active peptic ulcer and hemorrhagic cerebrovascular accident; 8. patients with severe impairment of renal function (creatinine clearance rate is less than 30ml/min); 9. patients with uncontrolled hypertension; 10. patients with acute bacterial endocarditis; 11. pregnant and lactating women; 12. patients who had participated in clinical trials of other drugs or medical devices within the past 3 months.;Exclusion criteria: 1. Patients who have accepted drug treatment outside of hospital; 2. patients who have long-term used antiplatelet or anticoagulant drugs; 3. patients with hematological diseases; 4. patients with trauma, fracture, stroke, paralysis, long-term bedridden, central venous catheter, Crohn's disease, nephrotic syndrome, long-term use of estrogen, malignant tumor, heart and lung failure, oral contraceptives, venous thromboembolism disease; 5. patients who are allergic to any excipient of low molecular heparin or low molecular weight heparin injection; 6. patients who have thrombocytopenia history while using low molecular weight heparin; 7. patients with active peptic ulcer and hemorrhagic cerebrovascular accident; 8. patients with severe impairment of renal function (creatinine clearance rate is less than 30ml/min); 9. patients with uncontrolled hypertension; 10. patients with acute bacterial endocarditis; 11. pregnant and lactating women; 12. patients who had participated in clinical trials of other drugs or medical devices within the past 3 months.;Exclusion criteria: 1. Patients who have accepted drug treatment outside of hospital; 2. patients who have long-term used antiplatelet or anticoagulant drugs; 3. patients with hematological diseases; 4. patients with trauma, fracture, stroke, paralysis, long-term bedridden, central venous catheter, Crohn's disease, nephrotic syndrome, long-term use of estrogen, malignant tumor, heart and lung failure, oral contraceptives, venous thromboembolism disease; 5. patients who are allergic to any excipient of low molecular heparin or low molecular weight heparin injection; 6. patients who have thrombocytopenia history while using low molecular weight heparin; 7. patients with active peptic ulcer and hemorrhagic cerebrovascular accident; 8. patients with severe impairment of renal function (creatinine clearance rate is less than 30ml/min); 9. patients with uncontrolled hypertension; 10. patients with acute bacterial endocarditis; 11. pregnant and lactating women; 12. patients who had participated in clinical trials of other drugs or medical devices within the past 3 months.;Exclusion criteria: 1. Patients who have accepted drug treatment outside of hospital; 2. patients who have long-term used antiplatelet or anticoagulant drugs; 3. patients with hematological diseases; 4. patients with trauma, fracture, stroke, paralysis, long-term bedridden, central venous catheter, Crohn's disease, nephrotic syndrome, long-term use of estrogen, malignant tumor, heart and lung failure, oral contraceptives, venous thromboembolism disease; 5. patients who are allergic to any excipient of low molecular heparin or low molecular weight heparin injection; 6. patients who have thrombocytopenia history while using low molecular weight heparin; 7. patients with active peptic ulcer and hemorrhagic cerebrovascular accident; 8. patients with severe impairment of renal function (creatinine clearance rate is less than 30ml/min); 9. patients with uncontrolled hypertension; 10. patients with acute bacterial endocarditis; 11. pregnant and lactating women; 12. patients who had participated in clinical trials of other drugs or medical devices within the past 3 months.;Exclusion criteria: 1. Patients who have accepted drug treatment outside of hospital; 2. patients who have long-term used antiplatelet or anticoagulant drugs; 3. patients with hematological diseases; 4. patients with trauma, fracture, stroke, paralysis, long-term bedridden, central venous catheter, Crohn's disease, nephrotic syndrome, long-term use of estrogen, malignant tumor, heart and lung failure, oral contraceptives, venous thromboembolism disease; 5. patients who are allergic to any excipient of low molecular heparin or low molecular weight heparin injection; 6. patients who have thrombocytopenia history while using low molecular weight heparin; 7. patients with active peptic ulcer and hemorrhagic cerebrovascular accident; 8. patients with severe impairment of renal function (creatinine clearance rate is less than 30ml/min); 9. patients with uncontrolled hypertension; 10. patients with acute bacterial endocarditis; 11. pregnant and lactating women; 12. patients who had participated in clinical trials of other drugs or medical devices within the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| thromboelastography; | — |
Countries
China
Contacts
Public ContactChen Dongfeng;Chen Dongfeng;Chen Dongfeng;Chen Dongfeng;Chen Dongfeng ;;;;
Daping Hospital, Third Military Medical University;Daping Hospital, Third Military Medical University;Daping Hospital, Third Military Medical University;Daping Hospital, Third Military Medical University;Daping Hospital, Third Military Medical University
Outcome results
None listed